Risk Mitigation in Preventing Adventitious Agent Contamination of Mammalian Cell Cultures

  • Masaru ShiratoriEmail author
  • Robert Kiss
Part of the Advances in Biochemical Engineering/Biotechnology book series (ABE, volume 165)


Industrial-scale mammalian cell culture processes have been contaminated by viruses during the culturing phase. Although the historical frequency of such events has been quite low, the impact of contamination can be significant for the manufacturing company and for the supply of the product to patients. This chapter discusses sources of adventitious agent contamination risk in a cell culture process, provides a semiquantitative assessment of such risks, and describes potential process barriers that can be used to reduce contamination risk. High-temperature, short-time (HTST) heat treatment is recommended as the process barrier of choice, when compatible with the process. A case study assessing the compatibility of HTST heat treatment with a cell culture medium is presented, and lessons learned are shared from our experiences over many years of developing and implementing virus barriers in mammalian cell culture processes.

Graphical Abstract


Contamination risk assessment HTST heat treatment Nanofiltration UV radiation Virus barriers Virus contamination 



We acknowledge many individuals too numerous to specifically name who, over the course of many years since the initial decision to develop and implement additional virus barriers, have contributed significant time and effort to ensuring success. It has truly taken a village.


  1. 1.
    CBER (1997) Points to consider in the manufacture and testing of monoclonal antibody products for human use. J Immunother 20(3):214–243Google Scholar
  2. 2.
    Knipe D, Howley P (2013) Fields virology. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  3. 3.
    Kiss R (2011) Practicing safe cell culture: applied process designs for minimizing virus contamination risk. PDA J Pharm Sci Technol 66:715–729CrossRefGoogle Scholar
  4. 4.
    FDA (1998) International Conference on Harmonisation; guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin (ICH Q5A). Fed Reg 63(185):51074–51084.Google Scholar
  5. 5.
    EMEA/CPMP/BWP/268/95/3AB8A (1996) Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of virusesGoogle Scholar
  6. 6.
    Kerr A, Nims R (2010) Adventitious viruses detected in biopharmaceutical bulk harvest samples over a 10 year period. PDA J Pharm Sci Technol 64:481–485PubMedGoogle Scholar
  7. 7.
    Bethencourt V (2009) Virus stalls Genzyme plant. Nat Biotechnol 27:681CrossRefGoogle Scholar
  8. 8.
    Chen J (2012) Case study: a novel bacterial contamination in cell culture production - Leptospira licerasiae. PDA J Pharm Sci Technol 66:580–591CrossRefPubMedGoogle Scholar
  9. 9.
    Garnick R (1996) Experience with viral contamination in cell culture. Dev Biol Stand 88:49–56PubMedGoogle Scholar
  10. 10.
    Nims R (2011) Adventitious viral contamination of biopharmaceuticals: who is at risk? BioProcess J 10:4–10CrossRefGoogle Scholar
  11. 11.
    Oehmig A, Buttner M, Weiland F, Werz W, Bergemann K, Pfaff E (2003) Identification of a calicivirus isolate of unknown origin. J Gen Virol 84:2837–2845CrossRefPubMedGoogle Scholar
  12. 12.
    Taleb NN (2007) The Black Swan the impact of the highly improbable. Random House, New YorkGoogle Scholar
  13. 13.
    Miesegaes G, Lute S, Aranha H, Brorson K (2010) Virus retentive filters. In: Flickinger M (ed) Encyclopedia of industrial biotechnology: bioprocess, bioseparation, and cell technology. Wiley, pp 1–11Google Scholar
  14. 14.
    Ruppach H (2014) Log10 reduction factors in viral clearance studies. BioProcess J:24–30CrossRefGoogle Scholar
  15. 15.
    Ge S (2014) Virus aerosol survivability, transmission, and sampling in an environmental chamber. DissertationGoogle Scholar
  16. 16.
    Boschetti N, Wyss K, Mischler A, Hostettler T, Kempf C (2003) Stability of minute virus of mice against temperature and sodium hydroxide. Biologicals 31:181–185CrossRefPubMedGoogle Scholar
  17. 17.
    Boschetti N, Niederhauser I, Kempf C, Stuhler A, Lower J, Blumel J (2004) Different suscepibility of B19 virus and mice minute virus to low pH treatment. Transfusion 44:1079–1086CrossRefPubMedGoogle Scholar
  18. 18.
    Sofer G, Lister D, Boose J (2003) Part 6, inactivation methods grouped by virus. BioPharm Int 6:S37–S42Google Scholar
  19. 19.
    Harris R, Coleman P, Morahan P (1974) Stability of minute virus of mice to chemical and physical agents. Appl Microbiol 28:351–354PubMedPubMedCentralGoogle Scholar
  20. 20.
    Murphy M, Quesada GM, Chen D (2011) Effectiveness of mouse minute virus inactivation by high temperature short time treatment technology: a statistical assessment. Biologicals 39:438–443CrossRefPubMedGoogle Scholar
  21. 21.
    Schleh M, Romanowski P, Bhebe P, Zhang L, Chinniah S, Lawrence B, Bashiri H, Gaduh A, Rajurs V, Rasmussen B, Chuck A, Dehghani H (2009) Susceptibility of mouse minute virus to inactivation by heat in two cell culture media types. Biotechnol Prog 25:854–860CrossRefPubMedGoogle Scholar
  22. 22.
    Nims R, Gauvin G, Plavsic M (2011) Gamma irradiation of animal sera for inactivation of viruses and mollicutes - a review. Biologicals 39:370–377CrossRefPubMedGoogle Scholar
  23. 23.
    Yen S, Sokolenko S, Manocha B, Blondeel E, Aucoin M, Patras A, Daynouri-Pancino F, Sasges M (2014) Treating cell culture media with UV irradiation against adventitious agents: minimal impact on CHO performance. Biotechnol Prog 30:1190–1195CrossRefPubMedGoogle Scholar
  24. 24.
    Chevrefils G, Caron E, Wright H (2006) UV dose required to achieve incremental log inactivation of bacteria, protozoa, and viruses. IUVA News 8:38–45Google Scholar
  25. 25.
    EMA (2012, 05 25) Press release: European Medicines Agency confirms positive benefit-risk balance of MabTheraGoogle Scholar
  26. 26.
    Pohlscheidt M, Charaniya S, Kulenovic F, Corrales M, Shiratori M, Bourret J, Meier S, Fallon E, Kiss R (2014) Implementing high-temperature short-time media treatment in commercial-scale cell culture manufacturing processes. Appl Microbiol Biotechnol 98:2965–2971CrossRefPubMedGoogle Scholar
  27. 27.
    Cao X, Stimpfl G, Wen ZQ, Frank G, Hunter G (2013) Identification and root cause analysis of cell culture media precipitates in the viral deactivation treatment with high-temperature/short-time method. PDA J Pharm Sci Technol 67:63–73CrossRefPubMedGoogle Scholar
  28. 28.
    Shiratori M, Kiss R, Prashad H, Iverson R, Bourret J, Kim M, Charaniya S (2012) Patent No. US 20130344570 A1. USAGoogle Scholar
  29. 29.
    Kuroda K, Okido M (2012) Hydroxyapatite coating of titanium implants using hydroprocessing and evaluation of their osteoconductivity. Bioinorganic Chem Appl 2012:2–7CrossRefGoogle Scholar
  30. 30.
    Hauser H, Wagner R (2014) Animal cell biotechnology in biologics production. De Gruyter, BerlinGoogle Scholar
  31. 31.
    Luo J, Zhang J, Ren D, Tsai W, Li F, Amanullah A, Hudson T (2012) Probing of C-terminal lysine variation in a recombinant monoclonal antibody production using Chinese hamster ovary cells with chemically defined media. Biotechnol Bioeng 109:2306–2315CrossRefPubMedGoogle Scholar
  32. 32.
    Vijayasankaran N, Varma S, Yang Y, Mun M, Arevalo S, Gawlitzek M, Swartz T, Lim A, Li F, Zhang B, Meier S, Kiss R (2013) Effect of cell culture medium components on color of formulated monoclonal antibody drug substance. Biotechnol Prog 29:1270–1277CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Genentech, Inc. (A Member of the Roche Group)San FranciscoUSA

Personalised recommendations